LDL Activators
DL Activators, as a chemical class, do not exist per se because LDL itself is not enzymatically active and does not have a direct activation state. However, discussing the functional activity of LDL in the context of biochemical pathways, we can consider compounds that influence LDL metabolism and clearance. For instance, statins indirectly enhance the functional activity of LDL by upregulating LDL receptor expression through inhibition of HMG-CoA reductase, which in turn lowers intracellular cholesterol and stimulates the liver to clear more LDL from the blood.
Moreover, compounds like cholestyramine and ezetimibe work by sequestering bile acids or inhibiting intestinal absorption of cholesterol, respectively. These actions lead to a compensatory increase in LDL receptor expression, which enhances the clearance of LDL cholesterol. PCSK9 inhibitors, such as evolocumab, represent another class that affects LDL metabolism by preventing the degradation of LDL receptors, thus maintaining their availability to clear LDL from the bloodstream.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
CHOLESTYRAMINE RESIN | 11041-12-6 | sc-507509 | 5 g | $210.00 | ||
Cholestyramine is a bile acid sequestrant that binds bile acids in the intestine, leading to their excretion. This loss of bile acids prompts the liver to convert more cholesterol into bile acids to compensate, indirectly increasing the uptake of LDL from the bloodstream by upregulating LDL receptor expression to replenish the cholesterol pool. Thus, cholestyramine enhances the functional activity of LDL by increasing its clearance from the blood. | ||||||
DL-Levothyroxine sodium | 1491-91-4 | sc-337686 | 1 g | $560.00 | ||
Thyroid hormones upregulate the expression of LDL receptors, leading to increased clearance of LDL from the blood. This action enhances the functional activity of LDL, as it is more effectively removed from circulation and delivered to the liver where it can be processed. | ||||||
Lomitapide-d8 | 182431-12-5 (unlabeled) | sc-489394 | 1 mg | $380.00 | ||
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor, which prevents the assembly of apolipoprotein B-containing lipoproteins in hepatocytes and enterocytes. This reduction in VLDL and chylomicron production results in decreased plasma LDL levels. By reducing the competition for LDL receptor-mediated uptake, lomitapide indirectly enhances the clearance of LDL, thus influencing LDL's functional activity. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $62.00 $124.00 | 1 | |
Niacin, also known as nicotinic acid, at pharmacological doses can reduce the hepatic synthesis of VLDL, which is the precursor of LDL. This leads to reduced LDL levels in the bloodstream. Niacin’s exact mechanism of action on LDL is not fully understood, but it is thought to enhance the clearance of LDL, indirectly increasing the functional activity of LDL. | ||||||
Eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoic Acid (20:5, n-3) | 10417-94-4 | sc-200766 sc-200766A | 100 mg 1 g | $104.00 $431.00 | ||
Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA), can modulate the expression and activity of enzymes involved in lipid metabolism, such as increasing the activity of lipoprotein lipase and decreasing the expression of hepatic lipase. This can lead to altered lipoprotein patterns favoring the enhanced clearance of LDL from circulation, thereby indirectly enhancing the functional activity of LDL. | ||||||
Berberine | 2086-83-1 | sc-507337 | 250 mg | $92.00 | 1 | |
Berberine is an alkaloid that has been shown to upregulate LDL receptors in hepatocytes through an AMPK-dependent pathway. By increasing the number of LDL receptors, berberine can enhance the catabolism of LDL, thus indirectly promoting its functional activity. | ||||||